For the last three years, the world has obsessed over generative AI that can write and create. By the end of 2026, we'll see ...

US biotech Aktis Oncology has filed IPO documents with the Securities and Exchange Commission (SEC), in what could be the ...

Traditional trial start-up workflows often follow a sequential path, from feasibility to contracting, then regulatory ...

Founded in 2014, Insilico finally pushed an IPO over the line last month, completing a much-oversubscribed listing on the ...

GSK has high hopes for Nucala thanks to its less frequent dosing – once a month, versus every other week for Dupixent – and ...

Sanofi could be months away from wider US approval for Tzield, its first-in-class drug for delaying the progression of type 1 ...

The Danish drugmaker said the drug will be available from today at prices starting from $149 per month for cash purchasers.

Today, the EU Council and Parliament reached an agreement in principle on the long-awaited pharma reform package, but Europe's drug industry has already said it will not be enough to keep the sector ...

The next iteration of FDA user fees could see the charges for programmes that run clinical early-stage trials in the US fall, and rise for those in which studies are conducted abroad, in a bid to ...

The FDA has lost no time in approving the first drug under its recently launched Commissioner's National Priority Voucher (CNPV) programme, clearing an antibiotic manufactured in the US. The fast ...

At ESMO 2025 in Berlin, VML Health – a global network of health communications experts that collaborate with patients, scientists, and creatives to improve lives – presented the inaugural Patient ...

An agreement between the UK and the US will maintain tariffs on imports into the US at 0% but, as a quid pro quo, prices of medicines used by the NHS will go up. The deal has been in the works since ...